Methotrexate Sodium
Brand name: Methotrexate
Rank #330 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$32.4M
Total Cost
911,965
Total Claims
$32.4M
Total Cost
10,058
Prescribers
$36
Cost per Claim
226,818
Beneficiaries
1,753,268
30-Day Fills
$3,225
Avg Cost/Provider
91
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$32.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $32.4M total
Top Prescribers of Methotrexate Sodium
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Bharath Manu Akkara Veetil | Internal Medicine | Saint Cloud, MN | 1,295 | $89K |
| 2 | Gerald Ho | Rheumatology | La Palma, CA | 1,431 | $65K |
| 3 | Frederick Murphy | Rheumatology | Duncansville, PA | 1,017 | $58K |
| 4 | Andrew Head | Rheumatology | Grand Rapids, MI | 799 | $56K |
| 5 | Mark Pearson | Rheumatology | Brookfield, WI | 1,149 | $56K |
| 6 | Anne Marie Holly | Physician Assistant | Rochester, NY | 1,297 | $54K |
| 7 | Hing-Sheung Fung | Internal Medicine | Waco, TX | 1,375 | $54K |
| 8 | Paul Utrie | Rheumatology | Green Bay, WI | 1,051 | $52K |
| 9 | Mujeeb Ranginwala | Rheumatology | Springfield, OH | 1,963 | $52K |
| 10 | Isam Diab | Rheumatology | Middleburg Hts, OH | 914 | $51K |
| 11 | Peter Kent | Rheumatology | St Louis Park, MN | 863 | $51K |
| 12 | Richard Martin | Rheumatology | Grand Rapids, MI | 765 | $51K |
| 13 | Maria Vintimilla | Rheumatology | New Smyrna Beach, FL | 1,856 | $50K |
| 14 | Sheila Albuquerque | Rheumatology | Houston, TX | 567 | $50K |
| 15 | William Surbeck | Rheumatology | Tulsa, OK | 1,136 | $49K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 327 | Budesonide (Budesonide Dr) | $33.1M | 120,202 |
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
| 333 | Rivastigmine (Rivastigmine) | $31.4M | 118,567 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology